Long-Term Outcome in Systemic Lupus Erythematosus; Knowledge from Population-Based Cohorts.

Systemic Lupus Erythematosus cancer end-stage renal disease epidemiology mortality outcome survival

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
22 Sep 2021
Historique:
received: 02 08 2021
revised: 06 09 2021
accepted: 13 09 2021
entrez: 13 10 2021
pubmed: 14 10 2021
medline: 14 10 2021
Statut: epublish

Résumé

Accurate knowledge of outcomes in Systemic Lupus Erythematosus (SLE) is crucial to understanding the true burden of the disease. The main objective of this systematic review was to gather all population-based studies on mortality, end-stage renal disease (ESRD) and cancer in SLE. We performed a systematic literature search in two electronic databases (MEDLINE and Embase) to identify all population-based articles on SLE and survival, mortality, ESRD and cancer. The SLE diagnosis had to be verified. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA). We included 40/1041 articles on mortality (27), ESRD (11) and cancer (3), of which six were defined as inception studies. In the total SLE cohort, the standardized mortality ratio ranged from 1.9 to 4.6. Cardiovascular disease was the most frequent cause of death in studies with follow-up times over 15 years. SLE progressed to ESRD in 5-11% of all SLE patients. There are no data supporting increased cancer incidence from population-based inception cohorts. There is a need for more population-based studies on outcomes of SLE, especially inception studies, with the use of control groups and follow-up times over 15 years.

Sections du résumé

BACKGROUND BACKGROUND
Accurate knowledge of outcomes in Systemic Lupus Erythematosus (SLE) is crucial to understanding the true burden of the disease. The main objective of this systematic review was to gather all population-based studies on mortality, end-stage renal disease (ESRD) and cancer in SLE.
METHOD METHODS
We performed a systematic literature search in two electronic databases (MEDLINE and Embase) to identify all population-based articles on SLE and survival, mortality, ESRD and cancer. The SLE diagnosis had to be verified. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA).
RESULTS RESULTS
We included 40/1041 articles on mortality (27), ESRD (11) and cancer (3), of which six were defined as inception studies. In the total SLE cohort, the standardized mortality ratio ranged from 1.9 to 4.6. Cardiovascular disease was the most frequent cause of death in studies with follow-up times over 15 years. SLE progressed to ESRD in 5-11% of all SLE patients. There are no data supporting increased cancer incidence from population-based inception cohorts.
CONCLUSION CONCLUSIONS
There is a need for more population-based studies on outcomes of SLE, especially inception studies, with the use of control groups and follow-up times over 15 years.

Identifiants

pubmed: 34640322
pii: jcm10194306
doi: 10.3390/jcm10194306
pmc: PMC8509465
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : The Dam Foundation
ID : 296618
Organisme : The Norwegian Women's Public Health Association
ID : 40108

Références

J Rheumatol. 2008 Oct;35(10):1978-82
pubmed: 18688913
Lupus. 2003;12(9):687-91
pubmed: 14514131
J Rheumatol. 2003 Apr;30(4):731-5
pubmed: 12672191
Lupus. 2016 Jun;25(7):727-34
pubmed: 26811368
Semin Arthritis Rheum. 2013 Aug;43(1):77-95
pubmed: 23422269
Clin Rheumatol. 1998;17(6):468-77
pubmed: 9890674
Am J Med. 2010 Dec;123(12):1150.e1-6
pubmed: 21183006
Lupus. 2020 Nov;29(13):1815-1820
pubmed: 32924832
Lupus. 2005;14(10):862-6
pubmed: 16302684
Medicine (Baltimore). 2005 Jul;84(4):218-224
pubmed: 16010206
Ann Rheum Dis. 2017 Dec;76(12):1992-2000
pubmed: 28780511
Best Pract Res Clin Rheumatol. 2017 Jun;31(3):373-396
pubmed: 29224679
Scand J Rheumatol. 2009 Mar-Apr;38(2):128-32
pubmed: 19117248
Rheumatology (Oxford). 2017 Nov 1;56(11):1945-1961
pubmed: 28968809
Int Immunopharmacol. 2021 May;94:107466
pubmed: 33636561
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Rheumatol. 1990 Sep;17(9):1162-7
pubmed: 2290155
Lupus. 2010 Feb;19(2):119-29
pubmed: 19946032
Int J Rheum Dis. 2013 Dec;16(6):747-53
pubmed: 24382283
J Rheumatol. 2014 Apr;41(4):680-7
pubmed: 24532834
Lupus. 2014 Dec;23(14):1546-52
pubmed: 25209070
Arthritis Care Res (Hoboken). 2012 Aug;64(8):1151-8
pubmed: 22392730
Lupus. 2013 Oct;22(11):1185-91
pubmed: 23873432
Rheumatology (Oxford). 2016 Feb;55(2):252-62
pubmed: 26342222
Arthritis Care Res (Hoboken). 2015 May;67(6):817-28
pubmed: 25369985
Autoimmun Rev. 2004 Aug;3(6):423-53
pubmed: 15351310
Medicine (Baltimore). 2011 Sep;90(5):350-358
pubmed: 21857367
Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i67-i77
pubmed: 27940583
J Rheumatol. 2000 Aug;27(8):1884-91
pubmed: 10955328
Am J Med. 1976 Feb;60(2):221-5
pubmed: 1251849
Medicine (Baltimore). 1989 May;68(3):141-50
pubmed: 2785628
Rheumatology (Oxford). 2012 Apr;51(4):663-9
pubmed: 22157467
Arthritis Rheumatol. 2014 Feb;66(2):369-78
pubmed: 24504809
J Autoimmun. 2012 May;38(2-3):J81-7
pubmed: 21813263
Arthritis Rheum. 1999 Jan;42(1):46-50
pubmed: 9920013
Int J Rheum Dis. 2016 Nov;19(11):1175-1182
pubmed: 26864331
Arthritis Care Res (Hoboken). 2016 Mar;68(3):357-65
pubmed: 26239749
Rheumatol Int. 2013 Jul;33(7):1805-11
pubmed: 23314932
J Rheumatol. 2001 Mar;28(3):539-46
pubmed: 11296955
J Rheumatol. 2009 Mar;36(3):552-9
pubmed: 19208593
Lupus. 2019 Jun;28(7):818-825
pubmed: 31072277
Lupus. 2016 Jun;25(7):772-80
pubmed: 26923282
Lupus. 2019 Oct;28(12):1488-1494
pubmed: 31551031
J Rheumatol. 2000 Mar;27(3):685-91
pubmed: 10743809
Nephrol Dial Transplant. 2011 Feb;26(2):620-7
pubmed: 20647194
Arthritis Rheumatol. 2014 Feb;66(2):357-68
pubmed: 24504808
Int J Rheum Dis. 2021 Jun;24(6):847-854
pubmed: 34058079
Scand J Rheumatol. 1998;27(2):98-105
pubmed: 9572634
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Lupus. 2016 Jan;25(1):102-9
pubmed: 26345673
Arthritis Care Res (Hoboken). 2014 Apr;66(4):608-16
pubmed: 24106157
MMWR Morb Mortal Wkly Rep. 2019 May 10;68(18):419-422
pubmed: 31071073
Lupus. 2001;10(7):500-4
pubmed: 11480849
Ann Rheum Dis. 1992 Nov;51(11):1197-201
pubmed: 1466595
Nephrol Dial Transplant. 2017 Oct 1;32(10):1683-1690
pubmed: 28011646
Am J Kidney Dis. 1994 Apr;23(4):547-54
pubmed: 8154491
Ann Rheum Dis. 2017 Dec;76(12):2009-2016
pubmed: 28794077
Arthritis Rheumatol. 2016 Jun;68(6):1432-41
pubmed: 26815601
Scand J Rheumatol. 1999;28(2):75-80
pubmed: 10229135

Auteurs

Sigrid Reppe Moe (S)

Department of Rheumatology, Oslo University Hospital, 0424 Oslo, Norway.

Hilde Haukeland (H)

Department of Rheumatology, Oslo University Hospital, 0424 Oslo, Norway.
Department of Rheumatology, Martina Hansens Hospital, 1346 Gjettum, Norway.

Øyvind Molberg (Ø)

Department of Rheumatology, Oslo University Hospital, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, 0424 Oslo, Norway.

Karoline Lerang (K)

Department of Rheumatology, Oslo University Hospital, 0424 Oslo, Norway.

Classifications MeSH